NEVRO CORP. (NYSE:NVRO) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07

On May 25, 2017, Nevro Corp. (the Company) held its Annual
Meeting of Stockholders (the Annual Meeting). At the Annual
Meeting, the Companys stockholders voted on three proposals, each
of which is described in more detail in the Companys definitive
proxy statement on Schedule 14A filed with the Securities and
Exchange Commission on April 12, 2017. Only stockholders of
record as of the close of business on April 3, 2017, the record
date for the Annual Meeting, were entitled to vote at the Annual
Meeting. As of the record date, 29,264,440 shares of the Companys
common stock were outstanding and entitled to vote at the Annual
Meeting. The tabulation of the stockholder votes on each proposal
brought before the Annual Meeting is as follows:

Proposal 1. The election of two directors to hold office until
the 2020 annual meeting of stockholders or until their respective
successor is elected:

Proposal 2. The ratification of the selection, by the audit
committee of the board of directors of the Company, of
PricewaterhouseCoopers LLP as the independent registered public
accounting firm of the Company for the fiscal year ending
December 31, 2017:

As a routine proposal under applicable rules, no broker non-votes
were recorded in connection with this proposal.

Proposal 3. The approval, on a non-binding, advisory basis, of
the compensation of the Companys named executive officers:

About NEVRO CORP. (NYSE:NVRO)

Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals. The Company’s Senza is designed to create electrical impulses from 2 hertz to 10 kilohertz (kHz), including its HF10 therapy. HF10 therapy delivers waveforms at 10 kHz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger.

NEVRO CORP. (NYSE:NVRO) Recent Trading Information

NEVRO CORP. (NYSE:NVRO) closed its last trading session down -2.17 at 68.83 with 787,673 shares trading hands.